Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 4/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | ACHE | P22303 | 4/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29631582 | 0.91 | MCHR1 (0.46) | SCN4ADRD4DRD2ACHECHRM2 | |
| SCHEMBL20597490 | 0.89 | SCN4A (0.56) | SCN4APOLBDRD4DRD2ACHE | |
| SCHEMBL20597348 | 0.89 | SCN4A (0.56) | SCN4APOLBDRD4DRD2ACHE | |
| SCHEMBL20597239 | 0.89 | SCN4A (0.56) | SCN4APOLBDRD4DRD2ACHE | |
| Hydrochloric Acid SCHEMBL2148297 | 0.88 | SCN4A (0.55) | SCN4APOLBDRD4DRD2ACHE | |
| SCHEMBL29601945 | 0.87 | GAA (0.48) | SCN4ADRD4DRD2ACHECHRM2 | |
| SCHEMBL2148134 | 0.87 | GAA (0.48) | SCN4ADRD4DRD2ACHECHRM2 | |
| SCHEMBL30894560 | 0.79 | ACHE (0.43) | ACHECHRM2CHRM3BCHE | |
| SCHEMBL6078330 | 0.78 | MCHR1 (0.52) | SCN4APOLBDRD4DRD2ACHE | |
| SCHEMBL6078322 | 0.78 | MCHR1 (0.52) | SCN4APOLBDRD4DRD2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3927689-B1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORP (KR) | 2024-01-24 | — | — | EP | claimed |
| US-20220144774-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORPORATION (KR) | 2022-05-12 | — | — | US | claimed |
| EP-3927689-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | Yuhan Corporation (KR) | 2021-12-29 | — | — | EP | claimed |
| WO-2020204647-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORPORATION (KR) | 2020-10-08 | — | — | WO | claimed |
| EP-3927689-B1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORP (KR) | 2024-01-24 | — | — | EP | disclosed |
| US-20220144774-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORPORATION (KR) | 2022-05-12 | — | — | US | disclosed |
| US-20220144774-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORPORATION (KR) | 2022-05-12 | — | — | US | disclosed |
| EP-3927689-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | Yuhan Corporation (KR) | 2021-12-29 | — | — | EP | disclosed |
| EP-3927689-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | Yuhan Corporation (KR) | 2021-12-29 | — | — | EP | disclosed |
| WO-2020204647-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORPORATION (KR) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020204647-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORPORATION (KR) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144774-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | JAK3, JAK1, JAK2 | SCN4A 869/4885POLB 2740/4885DRD4 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.